Go Pro
→ Small Colorado Company (Backed by Sam Altman) Could Save U.S. Power Grid (From Altimetry) (Ad)tc pixel
NASDAQ:IFRX

InflaRx Q3 2025 Earnings Report

InflaRx logo
$1.72 +0.01 (+0.58%)
Closing price 10/2/2026 04:00 PM Eastern
Extended Trading
$1.76 +0.04 (+2.44%)
As of 10/2/2026 07:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

InflaRx EPS Results

Actual EPS
-$0.16
Consensus EPS
-$0.16
Beat/Miss
Met Expectations
One Year Ago EPS
N/A

InflaRx Revenue Results

Actual Revenue
$0.03 million
Expected Revenue
$0.03 million
Beat/Miss
Met Expectations
YoY Revenue Growth
N/A

InflaRx Announcement Details

Quarter
Q3 2025
Date
11/10/2025
Time
Before Market Opens
Conference Call Date
Monday, November 10, 2025
Conference Call Time
4:00PM ET

Upcoming Earnings

InflaRx's Q3 2026 earnings is estimated for Monday, November 9, 2026, based on past reporting schedules, with a conference call scheduled on Friday, November 6, 2026 at 12:30 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Conference Call Resources

Powered by Quartr

Earnings Documents

InflaRx's Q3 2025 Earnings ReleaseEarnings Release
(6-K)

InflaRx Earnings Headlines

Critical Analysis: TScan Therapeutics (NASDAQ:TCRX) and InflaRx (NASDAQ:IFRX)
October 3 at 2:15 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31081657
InflaRx Appoints Gabriela Alperovich, MD, PhD, as Senior Vice President and Global Head of Clinical Development
October 2 at 12:58 AM  |  marketscreener.comM
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - but now he believes he's found something better. This under-the-radar company sits at the intersection of America's two most important industries, including AI, pays massive dividends, and attracted a famous money manager who put 60% of his multi-billion-dollar fund into it. Tilson is revealing the name and ticker symbol completely free - no credit card or email required.tc pixel
October 3 at 1:00 AM  |  Stansberry Research (Ad)
InflaRx N.V. Selected for Late-Breaking Kidney Week 2026 Poster on Izicopan Kidney Disease Models
October 2 at 7:51 AM  |  quiverquant.comQ
InflaRx to Present Late-Breaking Pre-clinical Data on Izicopan at Kidney Week 2026
October 2 at 7:30 AM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/10/02/3373754/0/en/inflarx-to-present-late-breaking-pre-clinical-data-on-izicopan-at-kidney-week-2026.html
InflaRx N.V.: InflaRx Appoints Gabriela Alperovich, MD, PhD, as Senior Vice President & Global Head of Clinical Development
October 1 at 12:05 PM  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-10/69730294-inflarx-n-v-inflarx-appoints-gabriela-alperovich-md-phd-as-senior-vice-president-global-head-of-clinical-development-399.htm
See More InflaRx Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like InflaRx? Sign up for Earnings360's daily newsletter to receive timely earnings updates on InflaRx and other key companies, straight to your email.

About InflaRx

InflaRx (NASDAQ:IFRX) (NASDAQ: IFRX) is a clinical-stage biopharmaceutical company focused on developing therapies for inflammatory and autoimmune diseases. The company’s research centers on the complement system, an important part of the immune response, with particular emphasis on blocking the activity of complement component C5a, which can contribute to excessive inflammation and tissue damage.

InflaRx’s lead product candidate is vilobelimab, a monoclonal antibody designed to selectively inhibit C5a while preserving other aspects of the complement system. Vilobelimab received U.S. Food and Drug Administration emergency use authorization under the name Gohibic for certain critically ill adults hospitalized with COVID-19. The company has also evaluated vilobelimab in other serious inflammatory conditions, including hidradenitis suppurativa, ANCA-associated vasculitis and pyoderma gangrenosum.

InflaRx was founded in 2007 and is headquartered in Jena, Germany, with operations serving the global biopharmaceutical market. The company continues to advance complement-targeted treatments through clinical development and research programs, including potential next-generation therapies intended to address inflammatory diseases with significant unmet medical needs. InflaRx is led by Chief Executive Officer and co-founder Niels Riedemann, M.D.

View InflaRx Profile
Earnings Tools